HAVCR2 and neoplasm: Interestingly, TIGIT expressed on tumor-infiltrating effector cells synergizes with other co-inhibitory molecules to dampen the immune response and promote effector cells dysfunction [184,185], so that the co-blockade of TIGIT/PD-1/TIM-3 restored exhausted CD8+ T cells and induced complete tumor rejection [116,176,186,187].